Fountain of Youth

The Fountain of Youth Ubertrend’s modern arc traces to a stage at San Francisco’s Museum of Modern Art near Moscone Center in the year 2000. On stage are a group of Wired panelists discussing the future of life extension — the art of living longer. At one point an audience member asks the inevitable question: “Will we ever be able to live forever?”

The answer startles everyone in attendance: “We will be able to turn off the genetic clock by 2080.”

That is music to the ears of Extropians, a group whose boundless belief and faith in science and technology fuels an expectation that life will carry on much longer than most could imagine. As Extropy Institute founder Max More puts it, “This is the fourth revolution in our history — the ultrahuman revolution.”

Twenty-four years on, the prediction looks less ridiculous than it did in the room. The cellular reprogramming work of Japanese Nobel laureate Shinya Yamanaka — whose 2006 induced pluripotent stem cells reset adult cells to their earliest “pluripotent” stage — is now the foundation of Altos Labs, the $3 billion 2022 startup backed by Jeff Bezos, where Yamanaka serves as senior scientific advisor. The genetic clock the Wired panelist promised to turn off is now the explicit target of a research apparatus that would have been unthinkable a generation earlier.

More than half a 1900-era lifetime has been added to longevity. The average U.S. lifespan then was 49 years. By 2024 it stood at 79.0 years, per the CDC’s National Center for Health Statistics — an increase of 30 years and a rebound of 0.6 year from 2023, which itself was the highest level since the pandemic. Females now live to 81.4, males to 76.5; the gender gap has narrowed to 4.9 years.

The compounding effect is generational. According to the U.S. Census Bureau, the 65-and-older population will represent 20% of the total U.S. population by 2030 and nearly double in size to 84 million by 2050. Today’s 65-year-old can expect 19.7 more years of life on average — 20.8 for women, 18.4 for men.

This population tidal wave will flood the world with lots of fearful flotsam. Transamerica’s 2025 research found Baby Boomer workers carried a median $270,000 in total household retirement savings, with only 27% reporting a written retirement strategy. The combined Social Security trust funds are projected to be depleted in 2034; the retirement-only OASI fund faces depletion a year earlier, in 2033. Pressure to keep working is relentless: historically, between May 2000 and May 2016, the share of Americans 65+ in part- or full-time employment rose from 13% to 19%. A 2015 Bankers Life study found 41% of Boomers still in the workplace expected to work beyond 69 — or never retire.

Sonia Arrison, author of 100 Plus: How the Coming Age of Longevity Will Change Everything, has argued that recently born babies could be the first generation to live to 150. The U.K.’s Office for National Statistics estimates that 35% of the 797,000 babies born in 2013 could still be alive in 2113. The math of the Fountain of Youth is no longer rhetorical. It is actuarial.

Evidence of the disruption surfaces each fall in Las Vegas, where some 4,000 healthcare professionals attend the Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine. Sessions run from “Sexual Health in the Older Woman” to “Fat Grafting: The Natural Filler.” The event’s exhibit hall at the Sands Expo & Convention Center features nearly 400 exhibitors catering to this fast-growing market.

A4M — the American Academy for Anti-Aging Medicine — launched in 1992 with just 12 physicians. By 2011, approximately 26,000 practitioners had received an A4M certificate. The field is not officially recognized by the American Medical Association or the American Board of Medical Specialties. That has not slowed it down.

The institutional capital arrived in waves. Calico Labs — short for California Life Company — was launched in 2013 by Google founders Sergey Brin and Larry Page with a $1.5 billion budget supplied by Alphabet and drug company AbbVie. Oracle founder Larry Ellison poured $430 million into his anti-aging Lawrence Ellison Foundation. Michael Milken and Jeff Bezos backed Unity Biotechnology, targeting senescent cells. Then came Altos Labs in January 2022 with $3 billion in committed capital, three Institutes of Science in San Francisco, San Diego and Cambridge, U.K., and a leadership team that reads like a Nobel reunion: Hal Barron from GSK as CEO, Rick Klausner (former National Cancer Institute director) as Chief Scientist, plus Shinya Yamanaka as senior scientific advisor.

The headline target is biological-age reversal. The clearest current proxy is the epigenetic clock, developed by UCLA’s Steve Horvath in 2013, which estimates biological age from DNA methylation patterns. Tech entrepreneur Bryan Johnson has spent the last four years running himself through every measured intervention in the open literature, publicly documenting an apparent biological-age slowdown of roughly 25% per chronological year. Tens of thousands now follow his “Don’t Die” protocol. The fringe has gone mainstream.

The Fountain of Youth is not a single industry. It is the alignment of three forces that have, individually and together, redirected hundreds of billions of dollars annually toward keeping the body in something like its earlier state. Each force has its own peer-reviewed literature and its own market cap.

The pharmacological frontier has matured in waves. Sirtuins and caloric restriction dominated the 2000s — Leonard Guarente’s Sir2 research, David Sinclair’s Sirtris (acquired by GlaxoSmithKline for $720 million in April 2008, shut down five years later when the drugs failed to deliver). Rapamycin — isolated from a bacterium in Easter Island soil in 1972 — inhibits the mTOR pathway and extends mouse lifespan in NIH-sponsored trials. The 2020s headline molecule, however, is GLP-1. Originally developed for type 2 diabetes, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) collectively generated over $50 billion in 2024 revenue across Novo Nordisk and Eli Lilly. The drugs reduce body weight by 15–22% in trial populations — effect sizes previously achievable only via bariatric surgery.

The aesthetic frontier industrialized in parallel. ASPS’s 2024 report counts 9.88 million neuromodulator injections, 5.33 million HA filler procedures, and 28.2 million total minimally invasive treatments. Surgical breast augmentation has settled at 306,196 procedures in 2024 — still 12% below the 2007 peak of 347,524, but a long way from the 2020 pandemic floor of 193,073. The mental model of the “before” and “after” has become a quarterly P&L for the publicly traded device-makers behind it.

The lifestyle frontier closes the loop. A 400,000-person Taiwanese cohort study published in The Lancet found that just 15 minutes of exercise daily was associated with a 3-year increase in life expectancy and a 14% reduction in all-cause mortality. The Copenhagen City Heart Study found a similar effect for moderate jogging: 6.2 additional years for men and 5.6 for women. Yoga participation reached 21 million in the U.S. by 2016. The Global Wellness Institute’s 2025 monitor pegs the total wellness economy at $6.8 trillion in 2024, up 7.9% from 2023.

If the Fountain has a payoff, it also has a cost. The pharmacological promise has, more often than not, underdelivered. Sirtris — acquired by GlaxoSmithKline in 2008 for $720 million on the premise that resveratrol-mimicking molecules would extend healthspan — was quietly shut down five years later. Elixir Pharmaceuticals, which had raised $99 million from nine investors on the same Sir2 thesis, disappeared. Cynthia Kenyon, who wrote the founding C. elegans paper, joined Calico. The science is real. The drugs have been harder.

Human growth hormone has a similar tail. By 2004, 74% of HGH prescriptions went to people over 20, with annual sales exceeding $622 million. Documented side effects include diabetes, glucose intolerance, prostate-cancer risk and breast enlargement. Dr. Fred Sattler at Keck School of Medicine notes that “a limited number of controlled studies suggest that GH supplementation in older men increases lean mass by ~2 kg, with similar reductions in fat mass.” The vanity-medicine market is larger than the medical-medicine market.

Cosmetic surgery culture has its own asymmetry. The chapter notes the unsettling phenomenon of teenagers seeking breast implants — most surgeons decline to operate on patients younger than 18, but the 18-to-21 cohort is fair game. Lululemon’s retail productivity of approximately $1,609 per square foot (2024) is impressive; the cultural pressure encoded in the same trend is less celebrated. Pope Francis, in a 2018 interview, called selfie culture an engine of alienation. The same critique applies, with revisions, to filler-and-Botox culture.

The GLP-1 revolution’s long tail will play out over the 2020s. Trials and post-marketing surveillance have flagged risks across pancreatitis, gallbladder disease, gastroparesis, muscle mass loss and rebound weight gain after discontinuation. Approximately 20–50% of GLP-1 patients discontinue within the first year — some for cost, some for side effects, some because the maintenance therapy is harder to sustain than the launch. The drugs are revolutionary. They are not a finished story.

The environmental bill is the largest one outstanding. The world now produces more than 450 million tonnes of plastic annually, with roughly 350 million tonnes becoming plastic waste each year. Recent estimates suggest 1 to 2 million tonnes enter the oceans annually — a slow-motion poisoning of the planetary commons. The Fountain of Youth’s emphasis on personal rejuvenation has not extended, in proportion, to planetary rejuvenation. The body lives longer; the planet does not.

The next ten years will be the most consequential in the history of human longevity research, by a wide margin. Three lines of work are converging.

First, cellular reprogramming moves from laboratory mice to early human protocols. Altos Labs’ San Diego and Cambridge institutes are running on the assumption that Yamanaka-style partial reprogramming can be made therapeutic without inducing tumors — the central safety problem. If it works, it doesn’t just slow aging. It reverses biological-age markers across tissues. Calico, parallel work at Cynthia Kenyon’s lab, and a half-dozen well-funded startups are converging on the same target. The first human trial readouts are expected mid-decade.

Second, the GLP-1 platform is being extended well beyond weight management. Phase III data has shown reductions in cardiovascular events, kidney disease progression and — in early signals — Alzheimer’s symptoms. The drug class is positioning to become the most consequential cardiometabolic intervention since statins. Oral formulations and longer-acting injectables are in late-stage development. The 2025–2030 picture likely includes once-monthly dosing, broader payer coverage, and a meaningful share of U.S. adults on a maintenance GLP-1.

Third, AI-driven discovery compresses the timeline on the longevity-target backlog. Isomorphic Labs (DeepMind’s drug-discovery spinout) and others are turning Demis Hassabis’s AlphaFold work into the substrate for systematic target identification across the senescence, mitochondrial-dysfunction and proteostasis frontiers. The pharmaceutical industry has, in effect, gained a structural-biology supercomputer. The compounding effects across the longevity portfolio could be substantial.

Sonia Arrison’s prediction — that recently born children could be the first generation to reach 150 — sounded fanciful in 2011. In 2026 it is the working hypothesis of a multi-billion-dollar research apparatus. The Fountain of Youth Ubertrend marches on, and could provide the spark for a society that needs to rewrite its retirement, healthcare and labor-market arithmetic in real time. The chapter is being written now.